Putnam Investments’s Fennec Pharmaceuticals FENC Stock Holding History

Putnam Investments’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-262,033	Closed	-$1.27M	–	907
2019 Q1	$1.27M	Hold	262,033	–	–	﹤0.01%	745
2018 Q4	$1.67M	Hold	262,033	–	–	﹤0.01%	664
2018 Q3	$2.15M	Sell	262,033 -1,400	-0.5%	-$13K	﹤0.01%	750
2018 Q2	$2.75M	Hold	263,433	–	–	0.01%	658
2018 Q1	$3.19M	Buy	263,433 +145,788	+124%	+$1.38M	0.01%	608
2017 Q4	$1.17M	Buy	+117,645	New	+$1.17M	﹤0.01%	870

Other funds holding FENC

SCA

Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

SCM

Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

USAA

United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Putnam Investments's FENC Position: Q2 2019 in Review

Putnam Investments sold out of Fennec Pharmaceuticals (FENC) in Q2 2019, closing a stake of 262,033 shares — an estimated $1.27M sold.

Putnam Investments first reported a position in FENC in Q4 2017 and held it in 6 quarters. The position peaked at $3.19M in Q1 2018. 30 funds tracked by Wall St. Rank hold FENC as of Q2 2019.

Putnam Investments reported no remaining Fennec Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Putnam Investments sold 262,033 Fennec Pharmaceuticals shares in Q2 2019, an estimated $1.27M.
Putnam Investments first reported a position in Fennec Pharmaceuticals in Q4 2017 and held it in 6 quarters.
Putnam Investments's Fennec Pharmaceuticals position peaked at $3.19M in Q1 2018.
30 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2019.

Based on Putnam Investments's 13F filing for Q2 2019, filed 14 Aug 2019.